Establishing Multi-Target RNAi Strategies for Complex Tumour Biology

• Exploring dual and multi-gene silencing approaches designed to overcome pathway redundancy
• Addressing tumour adaptation and resistance mechanisms through combinatorial targeting
• Improving treatment responses across heterogeneous cancer populations

Speakers:

Crystal Jin

Co-Founder & Chief Executive Officer

Bound Therapeutics